Ubiquitin recognition of BAP1: understanding its enzymatic function

被引:6
|
作者
Hanpude, Pranita [1 ,2 ]
Bhattacharya, Sushmita [1 ]
Singh, Abhishek Kumar [1 ]
Maiti, Tushar Kanti [1 ]
机构
[1] Reg Ctr Biotechnol, Lab Funct Prote, NCR Biotech Sci Cluster, 3rd Milestone Gurgaon Faridabad Expressway, Faridabad 121001, Haryana, India
[2] Manipal Univ, Dept Biotechnol, Manipal 576104, Karnataka, India
关键词
C-TERMINAL HYDROLASES; BRCA1-ASSOCIATED PROTEIN-1; DEUBIQUITINATING ENZYME; MALIGNANT MESOTHELIOMA; SUBSTRATE-SPECIFICITY; MUTATIONS PREDISPOSE; TUMOR-SUPPRESSOR; ACTIVE-SITE; ACTIVATION; COMPLEX;
D O I
10.1042/BSR20171099
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
BRCA1-associated protein 1 (BAP1) is a nuclear localizing UCH, having tumor suppressor activity and is widely involved in many crucial cellular processes. BAP1 has garnered attention for its links with cancer, however, the molecular mechanism in the regulation of cancer by BAP1 has not been established. Amongst the four UCHs, only BAP1 and UCHL5 are able to hydrolyze small and large ubiquitin adducts but UCHL5 hydrolyzes only when it is present in the PA700 complex of the proteasome. The ability of BAP1 to cleave large ubiquitin derivatives is because of its relatively longer active-site crossover loop than other UCHs. The mechanism of ubiquitin recognition has not been studied for BAP1. The comparative enzymatic analysis of ubiquitin C-terminal hydrolase L1 (UCHL1), ubiquitin C-terminal hydrolase L3 (UCHL3), ubiquitin C-terminal hydrolase L5 (UCHL5N), and BAP1N has confirmed that enzymatically BAP1 is similar to UCHL5, which corroborates with the bioinformatics analysis done earlier. We have undertaken extensive mutational approaches to gain mechanistic insight into BAP1-ubiquitin interaction. Based on the homology-modeled BAP1 structure, we have identified a few BAP1 residues which possibly play a crucial role in ubiquitin interaction of which a few mutations have been identified in many cancers. Our comparative thermodynamic analysis reveals that BAP1-ubiquitin interaction is majorly driven by entropy factor which is unique amongst UCHs. Our study sheds light on BAP1 interaction with ubiquitin, which will be useful in understanding its enzymatic function.
引用
收藏
页数:15
相关论文
共 50 条
  • [41] Loss of Bap1 Expression in Non-Melanoma Skin Cancer in Patients With Germline BAP1 Mutations
    Mochel, Mark
    Piris, Adriano
    Nose, Vania
    Hoang, Mai
    LABORATORY INVESTIGATION, 2015, 95 : 124A - 124A
  • [42] Loss of BAP1 function leads to EZH2-dependent transformation
    Lindsay M LaFave
    Wendy Béguelin
    Richard Koche
    Matt Teater
    Barbara Spitzer
    Alan Chramiec
    Efthymia Papalexi
    Matthew D Keller
    Todd Hricik
    Katerina Konstantinoff
    Jean-Baptiste Micol
    Benjamin Durham
    Sarah K Knutson
    John E Campbell
    Gil Blum
    Xinxu Shi
    Emma H Doud
    Andrei V Krivtsov
    Young Rock Chung
    Inna Khodos
    Elisa de Stanchina
    Ouathek Ouerfelli
    Prasad S Adusumilli
    Paul M Thomas
    Neil L Kelleher
    Minkui Luo
    Heike Keilhack
    Omar Abdel-Wahab
    Ari Melnick
    Scott A Armstrong
    Ross L Levine
    Nature Medicine, 2015, 21 : 1344 - 1349
  • [43] Comparing the Prognostic Value of BAP1 Mutation Pattern, Chromosome 3 Status, and BAP1 Immunohistochemistry in Uveal Melanoma
    van de Nes, Johannes A. P.
    Nelles, Jasmin
    Kreis, Stefan
    Metz, Claudia H. D.
    Hager, Thomas
    Lohmann, Dietmar R.
    Zeschnigk, Michael
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2016, 40 (06) : 796 - 805
  • [44] Loss of BAP1 function leads to EZH2-dependent transformation
    LaFave, Lindsay M.
    Beguelin, Wendy
    Koche, Richard
    Teater, Matt
    Spitzer, Barbara
    Chrarniec, Alan
    Papalexi, Efthymia
    Keller, Matthew D.
    Hricik, Todd
    Konstantinoff, Katerina
    Micol, Jean-Baptiste
    Durham, Benjamin
    Knutson, Sarah K.
    Campbell, John E.
    Blum, Gil
    Shi, Xinxu
    Doud, Emma H.
    Krivtsov, Andrei V.
    Chung, Young Rock
    Khodos, Inna
    de Stanchina, Elisa
    Ouerfelli, Ouathek
    Adusumilli, Prasad S.
    Thomas, Paul M.
    Kelleher, Neil L.
    Luo, Minkui
    Keilhacke, Heike
    Abdel-Wahab, Omar
    Melnick, Ari
    Armstrong, Scott A.
    Levine, Ross L.
    NATURE MEDICINE, 2015, 21 (11) : 1344 - 1349
  • [45] Malignant Mesothelioma, BAP1 Immunohistochemistry, and VEGFA: Does BAP1 Have Potential for Early Diagnosis and Assessment of Prognosis?
    Pulford, Emily
    Huilgol, Kalyani
    Moffat, David
    Henderson, Douglas W.
    Klebe, Sonja
    DISEASE MARKERS, 2017, 2017
  • [46] G-quadruplexes in the BAP1 promoter positively regulate its expression
    Li, Yingzhou
    Zhang, Xiao
    Gao, Yang
    Shi, Jinming
    Tang, Liping
    Sui, Guangchao
    EXPERIMENTAL CELL RESEARCH, 2018, 369 (01) : 147 - 157
  • [47] Mesothelioma in a Setting of Germline BAP1 Mutations
    Carbone, Michele
    Pass, Harvey
    Yang, Haining
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S61 - S61
  • [48] The diagnostic role of BAP1 in serous effusions
    Davidson, Ben
    Totsch, Martin
    Wohlschlaeger, Jeremias
    Hager, Thomas
    Pinamonti, Maurizio
    HUMAN PATHOLOGY, 2018, 79 : 122 - 126
  • [49] A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma
    Wadt, K. A. W.
    Aoude, L. G.
    Johansson, P.
    Solinas, A.
    Pritchard, A.
    Crainic, O.
    Andersen, M. T.
    Kiilgaard, J. F.
    Heegaard, S.
    Sunde, L.
    Federspiel, B.
    Madore, J.
    Thompson, J. F.
    McCarthy, S. W.
    Goodwin, A.
    Tsao, H.
    Jonsson, G.
    Busam, K.
    Gupta, R.
    Trent, J. M.
    Gerdes, A. -M.
    Brown, K. M.
    Scolyer, R. A.
    Hayward, N. K.
    CLINICAL GENETICS, 2015, 88 (03) : 267 - 272
  • [50] BAP1-defficient breast cancer in a patient with BAP1 cancer syndrome
    Blatnik, Ana
    Ribnikar, Domen
    Dragos, Vita Setrajcic
    Novakovic, Srdjan
    Stegel, Vida
    Kuzmanov, Biljana Grcar
    Boc, Nina
    Peric, Barbara
    Skerl, Petra
    Klancar, Gasper
    Krajc, Mateja
    BREAST CANCER, 2022, 29 (05) : 921 - 927